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Background: H1N1 influenza viruses mutate rapidly, rendering vaccines developed in any given year relatively
ineffective in subsequent years. Thus it is necessary to generate new vaccines every year, but this is time-consuming
and resource-intensive. Should a highly virulent influenza strain capable of human-to-human transmission emerge,
these factors will severely limit the number of people that can be effectively immunised against that strain in time to
prevent a pandemic. An adjuvant and mode of administration capable of rendering ordinarily unprotective vaccine
doses protective would thus be highly advantageous.
Methods: The carbohydrate mannan was conjugated to whole inactivated H1N1 influenza virus at a range of ratios,
and mixed with it at a range of ratios, and various doses of the resulting preparations were administered to mice via
the intranasal (IN) route. Serum immunity was assessed via antigen-specific IgG ELISA and the haemagglutination-
inhibition (HI) assay, and mucosal immunity was assessed via IgA ELISA of bronchio-alveolar lavages.
Results: IN-administered inactivated H1N1 mixed with mannan induced higher serum IgG and respiratory-tract IgA
than inactivated H1N1 conjugated to mannan, and HIN1 alone. Adjuvantation was mannan-dose-dependent, with
100 μg of mannan adjuvanting 1 μg of H1N1 more effectively than 10 or 50 μg of mannan. Serum samples from
mice immunised with 1 μg H1N1 adjuvanted with 10 μg mannan did not inhibit agglutination of red blood cells
(RBCs) at a dilution factor of 10 in the HI assay, but samples resulting from adjuvantation with 50 and 100 μg mannan
inhibited agglutination at dilution factors of ≥ 40. Both serum IgG1 and IgG2a were induced by IN mannan-
adjuvanted H1N1 vaccination, suggesting the induction of humoral and cellular immunity.
Conclusions: Mixing 100 μg of mannan with 1 μg of inactivated H1N1 adjuvanted the vaccine in mice, such that IN
immunisation induced higher serum IgG and respiratory tract IgA than immunisation with virus alone. The serum from
mice thus immunised inhibited H1N1-mediated RBC agglutination strongly in vitro. If mannan similarly adjuvants low
doses of influenza vaccine in humans, it could potentially be used for vaccine ‘dose-sparing’ in the event that a vaccine
shortage arises from an epidemic involving a highly virulent human-to-human transmissable influenza strain.
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Currently, H1N1 vaccines are administered unadju-
vanted intramuscularly and rely on the induction of
serum IgG to induce protection. Estimating the vaccine
efficacy (VE) of this strategy in a broad sense is compli-
cated by the fact that from year to year the strains
chosen for inclusion match the actual emerging strains
to varying degrees; thus data collected one year cannot
be directly compared to data collected the next. Vaccin-
ation is clearly far from 100% efficacious, with a recent
large-scale 'sentinel' study calculating an overall VE of
47% [1]. Immunising with live attenuated virus at the
site of influenza virus entry, i.e. intranasally (IN), has
been investigated in humans and results suggest that a
regime based on or including IN immunisation may
enhance VE, and may be more effective in generating
heterotypic immunity [2,3].
Recent threats of the potential large-scale emergence
of human-to-human transmissible forms of virulent
H5N1 (reviewed in Kaplan et al. [4]) and H7N9 (reviewed
in Wu et al. [5]) avian influenza strains, and the actual
emergence of widespread human-to-human transmissible
variants of an H1N1 variant dubbed ‘swine-flu’ (reviewed
in Dhama et al. [6]) have highlighted the need for a non-
toxic, cost-effective dose-sparing influenza vaccine adju-
vant. An adjuvant that substantially reduces the amount
of influenza virus normally required for protective vaccin-
ation would allow for faster immunisation of potentially
high-risk sections of the population such as children and
asthmatics, against a rapidly emerging, highly virulent
influenza strain.
In this study, we investigated the ability of mannan to
adjuvant whole inactivated H1N1 (A/New Caledonia 20/
1999) influenza virus in mice. Mannan is a non-toxic
carbohydrate produced in most plants and yeasts, and it
has been administered parentarally to over 200 humans
as part of previous clinical trials in cancer, without
adverse events [7-9]. Based on previous reports that IN
immunisation of mice with mannan conjugated to anti-
gen induces both mucosal IgA and serum IgG [10], mice
were vaccinated via the intranasal route. Our initial
studies focused on vaccination with preparations com-
prised of whole influenza virus conjugated to oxidised
mannan, in an effort to target the virus directly to DCs,
via the mannose receptor [11,12]. Surprisingly, while
H1N1 conjugated to mannan was no more immuno-
genic than H1N1 alone, mixing free mannan with H1N1
yielded substantially greater serum IgG and IgA titres,
and IgA titres in the lung.
After determining that extending the intervals between
immunisations enhanced the induction of lung IgA, we
then tested varying amounts of mannan mixed with a
constant low dose of H1N1; while a small amount of
mannan had proven unable to adjuvant a small amountof H1N1, we hypothesised that a large amount of man-
nan may be able to. Further, it was hypothesised that
using the protracted immunisation schedule, substantial
lung IgA and serum IgG may be induced after two
immunisations, without the need for a third. These stra-
tegies proved successful, with two intranasal immunisa-
tions of 1 μg of H1N1 mixed with 100 μg of mannan
inducing lung IgA, serum IgG1 and IgG2a, and serum
immunity capable of neutralising the haemagglutination
capacity of the virus in vitro.
Methods
Influenza virus and mice
Egg-grown H1N1 (A/New Caledonia/20/1999) virus puri-
fied by sucrose gradient, concentrated, and inactivated
with ß-propiolactone was kindly provided by the WHO
Collaborating Centre for Reference and Research on Influ-
enza (North Melbourne, Australia). All mice were female
BALB/c sourced from the Walter and Elisa Hall Institute
(Melbourne, Australia), and were 8–10 weeks of age at
first immunisation. All mouse-work was conducted at the
Austin Hospital Animal Facility (Melbourne, Australia) in
accordance with an animal ethics application approved by
the Austin Animal Ethics Committee.
H1N1 mannan conjugates and H1N1 mannan mixes
Whole inactivated H1N1 was conjugated to oxidised
mannan via the conjugation method described in Stambas
et al. [10]. Mannan (1 mL of 14 mg/mL) in 0.1 M phos-
phate pH 6.0 was oxidised with the addition of 0.1 M
sodium periodate (100 μL in water) in the dark at 4°C for
1 hr. The mixture was quenched with 10 μL ethanediol
and reacted for a further 30 min as before. The oxidised
mannan mixture was passed through a PD10 column (GE
Biosciences) pre-equilibrated with 0.05 M bicarbonate
pH 9.0 to remove byproducts. The eluted 2 mL fraction
of oxidised mannan (7 mg/mL) after void volume
(2.5 mL) was collected. The resulting conjugate was used
without further purification. In previous studies we have
optimised the conjugation of mannan to recombinant
cancer-associated antigens [13] as well as bacterial [10]
and viral proteins. The periodate oxidation condition for
mannan was chosen such that aldehyde residues are gen-
erated from only a fraction of oxidised mannose units of
the mannan, without affecting its C-type lectin binding
activity [14-17]. For a complex antigen such as a whole
inactivated virus we expect the majority of conjugation of
mannan aldehyde groups to take place only at the
exposed amino groups, forming Schiff base linkages. To
identify optimal conjugation conditions, various amounts
of whole virus (36 μg, 18 μg and 9 μg) were separately
reacted with 350 μg of oxidised mannan, and the resulting
preparations were analysed by gel electrophoresis. The
oxidised mannan-H1N1 conjugates were filter-sterilised
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tion of H1N1 was based on the total amount of H1N1
used for conjugation. Mixtures of H1N1 and mannan
were generated by diluting the H1N1 stock (from 2.7 mg/
mL) and the mannan stock (from 14 mg/mL) in sterile
PBS, such that the desired dose of each was contained per
50 μL; the volume of each individual vaccination.Immunisation method
All immunisations were administered via the intranasal
route. While completely anaesthetised (via methoxyfluo-
rane inhalation) and held upright, 5-μL drops were gently
pipetted alternately into each nostril. The total volume of
every immunisation was standardised to 50 μL, regardless
of H1N1 dose or mannan dose. All mannan used through-
out the study was derived from Sacharomyces cerevisiae,
and sourced from Sigma (product# M7504-5G).Figure 1 Efficiency of oxidised mannan-H1N1 conjugation.
Conjugates of H1N1 and oxidised mannan (H1N1_OxMan) were
generated at ratios of 1:10, 1:5 and 1:2.5 and analysed by gel
electrophoresis followed by silver staining. Lane 1 = standards,
2 = H1N1 alone, 3 = 1:10, 4 = 1:5, 5 = 1:2.5.H1N1 mannan conjugate vs. mannan mixture
To ascertain the immunogenicity of H1N1 conjugated to
oxidised mannan or mixed with mannan with regard to
induction of serum IgG, groups of 5 mice were immunised
intranasally with H1N1 alone, H1N1 conjugated to man-
nan (H1N1_OxMan) or H1N1 mixed with mannan
(H1N1 +mannan). Initially, two doses of virus were tested,
0.4 μg and 10.0 μg. When generating the H1N1_OxMan
conjugates, a 10:1 ratio of mannan:H1N1 was used (see
Figure 1). Thus, in the comparable ‘mannan mixed’ condi-
tions this ratio was maintained; mice receiving 0.4 μg of
H1N1 received 4 μg of mannan, and those receiving 10 μg
of H1N1 received 100 μg of mannan. Mice were immu-
nised twice, 10 days apart, then serum was collected 5 days
after the second immunisation and assayed for anti-H1N1
IgG.
To investigate the potential for mannan to adjuvant
the induction of IgA, groups of 9 mice were then immu-
nised three times (days 0, 10 and 17) with 10 μg of
H1N1 either alone, conjugated to 100 μg of mannan or
mixed with 100 μg of mannan. Serum was harvested
from all mice 7 days after the final immunisation, and
lung washes were performed on 5 mice from each group.
All samples were assayed for anti-H1N1 IgA by ELISA.Mannan mixture with extended immunisation intervals
We then assessed whether increasing the time between
immunisations and delaying lung wash harvesting
yielded greater respiratory tract IgA, as isotype conver-
sion to IgA is known to occur over weeks, rather than
days [18]. A subgroup of mice was immunised with
10 μg of H1N1 mixed with 100 μg of mannan three
times at 14-day intervals, and lung washes were col-
lected 14 days after the final immunisation.Increased mannan dose in H1N1 mixture
We then assessed whether a large amount of mannan
could boost the immune response to a small amount of
antigen. We also tested whether by using the previously
investigated extended interval between immunisations
(14 days), substantial serum IgG and lung IgA were
induced in mice after two immunisations, negating the
requirement for a third. Mice were immunised with 1 μg
of H1N1 mixed with 10, 50 or 100 μg of mannan twice,
14 days apart. Fourteen days after the second immunisa-
tion, serum was harvested and assayed for anti-H1N1
IgG.
Serum and bronchio-alveolar-lavage collection
Serum was collected via retro-orbital bleed as described
in Donovan et al. [19]. Bronchio-alveolar-lavage (BAL)
fluid was collected after mice were euthanised via an
intraperitoneally-administered preparation consisting of
66 μL xylazil, 166 μL ketamine, and 266 μL saline. Tissue
was removed to expose the upper trachea, and a small
incision was made therein. With the aid if a blunt needle
attached to a 1 mL syringe, 1 mL of PBS was gently
flushed into the lungs, and drawn back out.
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ELISAs were performed using the HRP/TMB system.
Plates were coated with whole inactivated H1N1 (A/New
Caledonia/20/1999) at a concentration of 1 μg/mL. Total
anti-H1N1 IgG was detected using directly HRP-
conjugated rat anti-mouse-IgG (GE healthcare, product #
RPN1231V) and IgG1, IgG2a and IgA were detected using
biotin-labelled primary antibodies from Pharmingen
(product numbers 553441, 553388 and 556978 respec-
tively), and secondary streptavidin-HRP from GE health-
care (product #346480). End-titre was defined as the last
value in the titration to remain above the corresponding
control value, where the control was calculated as the
mean OD values + 2SD of naive mouse serum samples
(3–5 mice) at each titration point.Haemagglutination inhibition assays
HI assays were performed according to standard pro-
tocols [20]. Sera were pre-treated with receptor
destroying enzyme (RDE) II (Deka Seiken Co. Ltd.,
Tokyo, Japan) at a ratio of 1:4 (v/v) at 37°C for
16 hrs, then the enzyme was inactivated by the
addition of an equal volume of 54.4 mM tri-sodium
citrate (Ajax Chemicals, Australia), and incubation at
56°C for 30 min. At room temperature, 25 μL of an
A/New Caledonia/20/1999 virus preparation was added to
25 μL of the RDE-treated serum preparation, then this
solution was titrated in two-fold dilutions in PBS from an
initial serum:diluent ratio of 1:10 to a final ratio of 1:1280.
Following a 1-hr incubation, 25 uL of a 1% (v/v) suspen-
sion of turkey RBCs was added to each well. Haemagglu-
tination was assessed via standard methods [20], after
30 min. Where no neutralising antibodies were present
RBC agglutination proceeded uninhibited, but where anti-
haemagglutinin (HA) serum immunity had been gener-
ated, neutralising antibody bound to the HA protein, inhi-
biting its ability to agglutinate the RBCs. Titres were
defined as the reciprocal of the highest dilution of serum
where haemagglutination was prevented.Results
H1N1/oxidised-mannan conjugates (H1N1_OxMan)
Before the administration of mannan conjugates to
mice, the most effective ratio of oxidised mannan:
H1N1 with regard to conjugation efficiency was deter-
mined, as described in the Methods section, above.
The ratio of 39 μg of inactivated H1N1 to 350 μg of
oxidised mannan (Figure 1, lane 3) resulted in the
most mannosylation as judged by the replacement of
discrete viral protein bands with a smear, due to gly-
cosylation with oxidised mannan, as described in
Apostolopoulos et al. [13] (Figure 1).Immunogenicity of H1N1_OxMan conjugates and
H1N1 +mannan mixes in mice
Unexpectedly, in the initial experiment H1N1_OxMan
was not more immunogenic than H1N1 alone with
regard to serum IgG, however 10 μg of H1N1 mixed with
100 μg of mannan induced higher titres of serum IgG
than 10 μg of H1N1 alone (p < 0.01, Bonferroni-corrected
multiple comparisons test) (Figure 2). No responses were
detected in any of the mice immunised with 0.4 μg H1N1
alone, conjugated to 4 μg mannan, or mixed with 4 μg
mannan. While intranasal immunisation with mannan
alone was not included in this experimental series, we
have previously ascertained that this induces no H1N1-
specific antibody as determined by ELISA and HI assays
(data not shown).
Mucosal antibody responses to H1N1_OxMan conjugates
and H1N1+ mannan mixes
After immunising groups of 9 mice three times (at days
0, 10 and 17) with 10 μg of H1N1 either alone, conju-
gated to 100 μg of mannan or mixed with 100 μg of
mannan, serum was harvested from all mice 7 days after
the final immunisation, and lung washes were performed
on 5 mice from each group. While immunisation with
H1N1 alone and H1N1_OxMan induced low levels of
serum IgA in some mice, H1N1 mixed with mannan
induced serum IgA in all mice (Figure 3a). Mucosal IgA
was only detected in the lungs of mice immunised with
H1N1 mixed with mannan (Figure 3b).
Optimisation of the immunogenicity of H1N1 +mannan
mixtures
A subgroup of mice was immunised with 10 μg of H1N1
mixed with 100 μg of mannan three times at 14-day
intervals, and lung washes were collected 14 days after
the final immunisation. Increasing the intervals between
immunisations and sample harvesting to 14 days re-
sulted in higher lung IgA titres (Figure 4), and was
adopted thereafter, throughout the rest of the study.
While a small amount of mannan was unable to adju-
vant a small amount of H1N1 (Figure 2), we hypothe-
sised that a large amount of mannan may be able to
boost the immune response to a small amount of anti-
gen. Further, it was hypothesised that by delaying
immunisation for 2-week intervals, substantial serum
IgG may be evident in mice after two immunisations,
without the requirement for a third. To test these
hypotheses, mice were immunised with 1 μg of H1N1
mixed with either 10, 50 or 100 μg of mannan twice,
14 days apart. Fourteen days after the final immunisa-
tion, serum was harvested and assayed for anti-H1N1
IgG. One hundred micrograms of mannan was able
to significantly adjuvant 1 μg of H1N1 after two
immunisations (Figure 5a), and thereafter 100 μg of
Figure 2 Immunogenicity of H1N1, H1N1_OxMan and H1N1 +mannan. Mice were immunised intranasally on days 0 and 10 with 0.4 or
10.0 μg of H1N1 alone, H1N1_OxMan or H1N1 mixed with mannan (H1N1 +mannan). Serum was harvested on day 15 and anti-H1N1 IgG activity
was determined by ELISA.
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out the rest of the study.
To confirm that the antibody induced by mannan-
adjuvanted H1N1 was likely to equate with in vivo
protection, serum from the immunised mice was
tested in an HI assay. Only serum from mice immu-
nised with H1N1 adjuvanted with 50 or 100 μg of
mannan was able to inhibit the ability of H1N1 to
agglutinate turkey RBCs. In previous studies [21], a
titre of ≥ 40 (indicated by the dashed line) correlated
with 50% protection against experimental infection
with partially attenuated challenge strains. In this study, noFigure 3 Mucosal antibody responses to H1N1_OxMan and H1N1 +m
10 μg of either H1N1 alone, H1N1_OxMan or H1N1 + 100 μg mannan. Ten da
samples were harvested and tested for anti-H1N1 IgA activity by ELISA assay.mice immunised with 1 μg H1N1 alone yielded HI titres
of ≥ 40, while all mice immunised with 1 μg H1N1 + 100 μg
of mannan yielded HI titres of ≥ 40 (p < 0.01, Fisher's exact
test) (Figure 5b).
To statistically validate the hypothesis that 100 μg of
mannan adjuvants antibody responses to 1 μg H1N1,
larger groups of mice were immunised twice at 14-day
intervals and serum was harvested 14 days after the
second immunisation. IgG1 and IgG2a isotypes were
detected separately, and the titres of both isotypes
were significantly enhanced via the inclusion of 100 μg
of mannan (p < 0.001, Mann–Whitney test) (Figure 6).annan. Mice were immunised intranasally on days 0, 10 and 17 with
ys after the final immunisation, (a) serum samples and (b) lung-wash
Figure 4 Differential vaccination kinetics and mucosal IgA
induction. Mice were immunised intranasally with 10 μg of H1N1
mixed with 100 μg of mannan either on days 0, 10 and 17 with
lung washes collected on day 22, or on days 0, 14 and 28 with lung
washes collected on day 32. The amounts of anti-H1N1 IgA in the
lung washes of individual mice were determined by ELISA.
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subgroup of mice from the above experimental series,
and assayed for IgA. IgA was evident in all but one of
the mice immunised with H1N1 +mannan (n = 10), but
was essentially absent in mice immunised with H1N1
alone (n = 5) (p < 0.01, Mann–Whitney test) (Figure 7).
The high variability in lung IgA titres within the ‘+ man-
nan’ group suggests that 1 μg H1N1 may correspond to
the approximate minimum H1N1 dose that can be ex-
pected to induce detectable lung IgA in the majority of
mice under the conditions tested.
Serum samples from three separate trials in which
mice were immunised with 1 μg of H1N1 alone or with
100 μg mannan intranasally 14 days apart were tested
for their ability to inhibit HA-protein mediated haem-
agglutination. While none of the serum samples from
mice immunised with H1N1 alone (n = 10) elicited HI
titres of ≥ 40 (mean titre = 6), 93% of mice immunisedFigure 5 Optimisation of H1N1:mannan ratio and serum haemaggluti
14 days apart with 1 μg H1N1 mixed with various amounts of mannan, and 1
IgG antibody, and (b) haemagglutination inhibition activity.with H1N1 +mannan mix (n = 15) elicited HI titres of ≥ 40
(mean titre = 456) (Figure 8).
Discussion
When the threat of an H5N1 pandemic emerged in
2005, the World Health Organisation (WHO) indicated
that research investigating flu adjuvants was a high pri-
ority. Identifying an effective ‘dose-sparing’ adjuvant was
deemed important due to the potential emergence of
new strains (reviewed in Fisman et al. [22]) and the lag
time involved in producing vaccine in live embryonated
chicken eggs.
In this study, the dose sparing potential of mannan as
an adjuvant for influenza was explored. The initial strat-
egy of conjugating mannan to whole influenza virus was
investigated based on previous observations suggesting
that this may promote targeting of antigen to DCs via the
mannose receptor [11,12]. However, while mannan-
conjugated whole virus proved no more immunogenic
that virus alone, unexpectedly, ‘free mannan’ adjuvanted
whole virus significantly. As our initial studies were
focused on mannan-influenza conjugates, the ratio of
mannan to H1N1 included in the ‘control’ (mannan
mixed) conditions was kept proportional to the amount
used to derive the conjugates; mice receiving low doses
of H1N1 received proportionally low amounts of man-
nan. However, once it was ascertained that mannan func-
tioned as an adjuvant when mixed with (rather than
conjugated to) whole influenza virus, we abandoned the
conjugation-based mannan to antigen ratio, and con-
firmed that 100 μg of free mannan was able to adjuvant a
single microgram of whole inactivated H1N1.
We investigated intranasal influenza vaccination as
this has been shown to stimulate the mucosal immune
response and generate secretory IgA at the site of infection
[23]. Encouragingly, in a large-scale multi-centre human
trial comparing intranasal (FluMist®) and intramuscularnation inhibition activity. Groups of mice were immunised twice
4 days after the last immunisation mouse sera were tested for (a) serum
Figure 8 Haemagglutination inhibition by serum from mice
immunisation with 1 μg of H1N1 adjuvanted with 100 μg of
mannan. Groups of mice were immunised twice 14 days apart with
1 μg of H1N1 alone or mixed with 100 μg mannan, and 14 days
after the second immunisation serum was harvested and assayed for
its ability to inhibit the agglutination of turkey RBCs by H1N1 in vitro.
Figure 6 IgG sub-class induction after immunisation with 1 μg
of H1N1 adjuvanted with 100 μg of mannan. Groups of mice
were immunised twice 14 days apart with 1 μg of H1N1 alone, or mixed
with 100 μg mannan, and 14 days after the last immunisation serum
was harvested and assayed for anti-H1N1 (a) IgG1 and (b) IgG2a by ELISA.
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IN immunisation was more protective than intramuscular
(IM) immunisation against naturally acquired infection in
infants [24]. Notably, the intranasal route is also more
amenable to ‘self-administration’ (via a nasal spray) than anFigure 7 Anti-H1N1 IgA in lung washes 14 days after two
intranasal immunisations with 1 μg of H1N1 mixed with 100 μg
of mannan. Mice were immunised twice 14 days apart with 1 μg of
H1N1 alone or mixed with 100 μg mannan, and 14 days after the last
immunisation lung washes were harvested and assayed for
anti-H1N1 IgA.intramuscular injection, which may prove advantageous
during a pandemic caused by a rapidly spreading newly
emergent influenza strain. Should a ‘booster’ (i.e. a second
vaccination) be required for example, this could be supplied
to the vaccinee at the time of their first vaccination (or sub-
sequently by a pharmacist), to be self-administered 2 weeks
after the first vaccine. Under this scenario, the first vaccine
could also conceivably actually be self-administered under
the careful guidance of a health-care professional, to ensure
that the vaccinee was confident and capable of self-
administering any subsequently required boosters. In a
‘similar vein’, in remote or disadvantaged communities
where infrastructure and health professionals are scarce, a
vaccine that negates the use of needles and could be self-
administered would conceivably be advantageous.
While it has previously been shown that IN administra-
tion of mannan-conjugated proteins generates antigen-
specific IgA in the lung [10], this is the first demonstration
of this using whole virus as antigen and free mannan as
adjuvant. The contribution of H1N1-specific lung IgA to
protection against a live influenza challenge is currently
under investigation. Both IgG2a and IgG1 were induced by
H1N1 +mannan in the present study, suggesting the in-
duction of cellular as well as humoral immunity. This
bodes well for the vaccine strategy, as it is widely held that
the generation of effective ‘heterotypic’ (cross-strain) im-
munity will require induction of a functional T cell
response. We are currently characterising the cellular
immunity induced by immunisation with mannan +H1N1
via a series of short peptides derived from each of the core
viral proteins.
To date we have been unable to definitively confirm
that the mannose receptor is involved in the mechanism
of adjuvantation by free mannan observed in the current
study, and notably other innate receptors may also be in-
volved [25]. Nevertheless, the observation that conjugation
is not required in the context of influenza adjuvantation is
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erations; it would conceivably be much easier to achieve
compositional standardisation across batches of GLP-
produced vaccine if ‘production’ merely entailed mixing
two homogenous GLP products together. Further, mannan
is an adjuvant well suited to en-masse vaccination as it is
very cheap, non-proprietary, easy to sterilise, store and
transport, and has proven to be non-toxic to humans when
delivered parenterally in clinical trials collectively compris-
ing > 200 patients [7-9].
The recent emergence of ‘swine flu’ (H1N1s) has rein-
forced the need for a dose-sparing influenza adjuvant. In
Australia [26] and New Zealand [27], after the rate of
the initial wave of H1N1s infections peaked (in approxi-
mately June/early July 2009) it then declined, but the
overall incidence of new infections remained significant,
to the extent that H1N1s actually ‘displaced’ the seasonal
A(H1N1) strain that had previously been predicted
would account for the majority of infections. Despite the
initial characterisation and isolation of the H1N1s strain
occurring in April 2009 [28], ‘growing up’ enough effect-
ive doses of the vaccine was by necessity time-
consuming, which contributed to the fact that vaccine
did not become available to the general public until
almost 6 months later, in early October. Before it
became clear that H1N1s posed no greater risk of mor-
tality than historical variants of the H1N1 ‘human’ flu,
the British Government evidently intended to immunise
more than half of its entire population against H1N1s
[29]. This would have been a massive endeavour, the
efficacy of which would have depended largely on the
speed at which it could have been implemented, which
would in turn have been limited by the rate of produc-
tion of effective vaccine doses. Implementation of a
dose-sparing influenza adjuvant that allowed, for exam-
ple, a five to ten-fold reduction in the amount of virus
constituting a protective dose would significantly reduce
the time between isolating a potentially pandemic influ-
enza strain, and generating enough virus to immunise
the population en-masse.Conclusions
Mannan successfully adjuvanted H1N1 vaccination in
mice, rendering otherwise weakly immunogenic doses
inductive of strong serum IgG, and IgA in the lung. As
mannan is cheap, non-toxic, non-proprietary, abundant
and easy to transport, it represents an attractive candi-
date adjuvant for rendering small doses of human influ-
enza vaccines more immunogenic (‘dose sparing’) in the
event of a pandemic involving a highly virulent and/or
transmissible strain; the results of the current study in
mice suggest that further studies in larger animals and/
or humans are warranted.Competing interests
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